Kailera Therapeutics (NASDAQ:KLRA) Shares Down 5.5% - Time to Sell?

Key Points

• Kailera Therapeutics shares fell 5.5% to $12.13, with trading volume down 62% from its average. The stock is also below its 50-day moving average of $17.03.
• Analyst sentiment is mixed: the consensus rating remains “Moderate Buy” with a $42.75 target price, but Wall Street Zen and Weiss Ratings issued sell ratings.
• The company reported a quarterly loss of $1.09 per share, missing estimates by $0.35, while analysts expect a full-year loss of $3.89 per share. Kailera is a clinical-stage biotech developing investigational obesity treatments, including the GLP-1 candidate KAIL-001.

Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report) shares were down 5.5% during trading on Monday . The company traded as low as $12.13 and last traded at $12.13. Approximately 287,447 shares changed hands during trading, a decline of 62% from the average session volume of 757,702 shares. The stock had previously closed at $12.83.

Wall Street Analysts Forecast Growth

KLRA has been the topic of a number of analyst reports. Wall Street Zen downgraded Kailera Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 30th. Weiss Ratings began coverage on Kailera Therapeutics in a research note on Friday, August 14th. They set a "sell (d)" rating for the company. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Kailera Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $42.75.

Kailera Therapeutics Price Performance

The stock has a fifty day simple moving average of $17.03. The stock has a market cap of $1.57 billion and a P/E ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.35). Equities research analysts forecast that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tidal Investments LLC acquired a new stake in shares of Kailera Therapeutics during the second quarter worth about $309,000. Squarepoint Ops LLC acquired a new position in shares of Kailera Therapeutics in the 2nd quarter valued at approximately $993,000. Frazier Life Sciences Management L.P. bought a new stake in Kailera Therapeutics during the 2nd quarter worth approximately $24,233,000. Wellington Management Group LLP bought a new stake in Kailera Therapeutics during the 2nd quarter worth approximately $64,308,000. Finally, Atlas Venture Life Science Advisors LLC acquired a new stake in Kailera Therapeutics during the 2nd quarter worth approximately $113,923,000.

Kailera Therapeutics Company Profile

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and related metabolic diseases. The company's programs are designed to address the substantial medical needs associated with excess weight and metabolic disorders.

Kailera's lead product candidate is KAIL-001, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of obesity and potentially related conditions. The company is advancing its pipeline through clinical development and regulatory activities, although its products remain investigational and are not yet approved for commercial use.

The company's operations are centered on the development of therapies for global markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.